Key Points
- Jonathan Slonin sold 3,261 shares on March 17 at an average price of $22.82 for about $74,416, reducing his holdings by 1.44% to 223,640 shares (≈$5.10M).
- Pacira missed its latest quarter, reporting EPS of $0.57 vs. $0.85 expected and revenue of $196.9M vs. $201.9M, though revenue rose 5.1% year‑over‑year.
- Analysts are mixed with a consensus "Hold" and a $30.75 average target; the stock trades at roughly a $896M market cap and a P/E of 147.29, and the company’s flagship product is EXPAREL, a non‑opioid postsurgical analgesic.
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) insider Jonathan Slonin sold 3,261 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the sale, the insider directly owned 223,640 shares of the company's stock, valued at approximately $5,103,464.80. This trade represents a 1.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Pacira BioSciences Stock Performance
Shares of NASDAQ:PCRX opened at $22.13 on Friday. The company's 50 day simple moving average is $21.72 and its 200 day simple moving average is $23.56. The stock has a market capitalization of $896.04 million, a price-to-earnings ratio of 147.29 and a beta of 0.21. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28. Pacira BioSciences, Inc. has a 1 year low of $18.80 and a 1 year high of $27.64.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.85 by ($0.28). The business had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The firm's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.91 earnings per share. As a group, research analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Wall Street Zen downgraded Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Needham & Company LLC reissued a "buy" rating and set a $30.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th. Barclays started coverage on shares of Pacira BioSciences in a report on Tuesday, December 9th. They issued an "equal weight" rating and a $27.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, Zacks Research cut shares of Pacira BioSciences from a "hold" rating to a "strong sell" rating in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $30.75.
View Our Latest Stock Report on Pacira BioSciences
Institutional Investors Weigh In On Pacira BioSciences
A number of institutional investors have recently added to or reduced their stakes in PCRX. PNC Financial Services Group Inc. raised its stake in shares of Pacira BioSciences by 17.8% during the second quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company's stock valued at $84,000 after acquiring an additional 531 shares during the last quarter. Inspire Investing LLC lifted its holdings in shares of Pacira BioSciences by 3.2% during the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company's stock worth $465,000 after purchasing an additional 556 shares during the period. Hantz Financial Services Inc. grew its stake in shares of Pacira BioSciences by 175.4% in the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock worth $29,000 after purchasing an additional 721 shares during the last quarter. State of Wyoming grew its stake in shares of Pacira BioSciences by 7.0% in the fourth quarter. State of Wyoming now owns 11,155 shares of the company's stock worth $289,000 after purchasing an additional 728 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Pacira BioSciences by 8.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 10,604 shares of the company's stock valued at $259,000 after purchasing an additional 785 shares during the period. 99.73% of the stock is owned by institutional investors.
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
